CHEK2 and hereditary cancer: We queried data available through cBioPortal and determined the frequency of somatic deleterious ATM variants and compared this alteration frequency to that of BRCA1 and CHEK2, as these are DNA-damage response tumor suppressors also implicated in hereditary cancer, but not established to drive oncogenesis in the cancer types being investigated.